烟囱腔内技术择期治疗肾旁主动脉病变的结局
该回顾性研究分析了165例择期接受烟囱腔内动脉瘤修复(CHEVAR)的无症状肾旁主动脉病变患者,植入244枚烟囱支架。中位随访25.5个月,30天及随访期手术相关死亡率为1.8%,原发和继发持续性IA内漏免除率分别为96.4%和99.4%,原发和继发烟囱支架通畅率分别为92.2%和95.9%。
要点
- 择期CHEVAR中期临床结果良好,与原发持续性IA内漏免除率96.4%、烟囱支架原发通畅率92.2%相关。
- 围手术期总并发症发生率为7.8%,包括肠缺血3例、肾缺血1例和卒中1例。
- 烟囱技术相关再干预率为10.9%,其中83.3%通过腔内方式完成。
核心结论
- 本系列中择期使用Endurant支架行CHEVAR的中期临床结果良好,与其他全腔内方式已发表结果相似。
- 需要前瞻性随机试验评估CHEVAR在择期肾旁主动脉病变治疗中的价值。
研究设计与样本
- 回顾性分析前瞻性收集的2009年3月至2018年1月期间165例连续无症状CHEVAR患者记录。
- 所有患者使用Endurant支架(Medtronic, Santa Rosa, Calif),共植入244枚烟囱支架。
- 主要终点为临床成功,定义为整个随访期内无手术相关死亡、持续性IA内漏、烟囱支架闭塞或高度狭窄(>70%)以及任何烟囱技术相关二次手术。
主要发现
- 全部244条目标烟囱血管成功置管。
- 围手术期总并发症发生率为7.8%(n=13),包括肠缺血3例(1.8%)、肾缺血1例(0.6%)和卒中1例(0.6%)。
- 中位随访25.5±2.2个月,30天和随访期手术相关死亡率均为1.8%(n=3)。
- 原发和继发持续性IA内漏免除率分别为96.4%(n=159)和99.4%(n=164)。
- 原发和继发烟囱支架通畅率分别为92.2%(n=225)和95.9%(n=234)。
关键数值与推荐
- 烟囱技术相关再干预率为10.9%(n=18),其中83.3%通过腔内方式完成。
- 估计累积原发通畅率和持续性IA内漏免除率分别为87.5%和95.3%。
- 中期原发和继发临床成功率分别为80.3%和87.5%。
临床怎么用
- 对于择期肾旁主动脉病变患者,CHEVAR可作为全腔内治疗的一种选择,中期结果与原发持续性IA内漏免除率96.4%、烟囱支架原发通畅率92.2%相关。
- 需注意围手术期并发症(7.8%)和烟囱技术相关再干预(10.9%),再干预多可通过腔内方式完成。
局限性
- 本研究为单中心回顾性分析,非随机对照。
- 仅纳入使用Endurant支架的病例,结论外推需谨慎。
- 随访时间有限(中位25.5个月),缺乏长期结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In the treatment of pararenal abdominal aortic aneurysms and aortic pathologic processes, chimney endovascular aneurysm repair (CHEVAR) represents an alternative technique for urgent cases. The aim of the study was to evaluate the outcomes of CHEVAR in the elective setting. METHODS: We performed a retrospective analysis of prospectively collected records of 165 consecutive asymptomatic CHEVAR patients who were treated between March 2009 and January 2018 with the Endurant stent graft (Medtronic, Santa Rosa, Calif). A total of 244 chimney grafts (CGs) were implanted. The primary end point was clinical success, defined as freedom from procedure-related mortality, persistent type IA endoleak, occlusion or high-grade stenosis (>70%) of CGs, and any chimney technique-related secondary procedure for the entire follow-up period. Secondary clinical success included patients with successful treatment of a primary end point with a secondary endovascular procedure. RESULTS: All 244 targeted chimney vessels were successfully cannulated. Total perioperative morbidity was 7.8% (n = 13), including 3 (1.8%) cases of bowel ischemia, 1 (0.6%) patient with renal ischemia, and 1 patient (0.6%) with stroke. Median follow-up was 25.5 ± 2.2 months. Both 30-day and follow-up procedure-related mortality rates were 1.8% (n = 3). Primary and secondary freedom from persistent type IA endoleak rates were 96.4% (n = 159) and 99.4% (n = 164), respectively. Primary and secondary CG patency rates were 92.2% (n = 225) and 95.9% (n = 234), respectively. The rate of reinterventions related to the chimney technique was 10.9% (n = 18), and 83.3% of them were performed by endovascular means. The estimated cumulative primary patency and freedom from persistent type IA endoleak were 87.5% and 95.3%, respectively, and the primary and secondary clinical successes rates at midterm were 80.3% and 87.5%, respectively. CONCLUSIONS: The elective use of CHEVAR with the Endurant stent graft in our series showed favorable midterm clinical results, which are similar to the published results of other total endovascular modalities. A prospective randomized trial of elective treatment of pararenal abdominal aortic aneurysms and aortic pathologic processes with current endovascular options is needed to assess the value of CHEVAR in the elective setting.
引用
- Pitoulias GA, Torsello G, Austermann M, et al. Outcomes of elective use of the chimney endovascular technique in pararenal aortic pathologic processes. J Vasc Surg. 2020. PMID: 32473338. doi:10.1016/j.jvs.2020.05.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。